传出细胞增多
免疫系统
免疫学
巨噬细胞
肠道菌群
医学
益生菌
炎症
系统性红斑狼疮
鼠李糖乳杆菌
自身免疫
自身抗体
吞噬作用
平衡
先天免疫系统
免疫毒理学
调解人
自身免疫性疾病
细胞因子
红斑狼疮
生物
免疫
促炎细胞因子
免疫失调
免疫耐受
作者
Ruimiao Wu,Mei Liu,Changxing Gao,Cheng Zhao,Feijie Zhao,Shuqing Dong,Bo Zhang,Qianmei Liu,Wenqian Zhang,Ming Zhao,Qianjin Lu
标识
DOI:10.1002/advs.202522637
摘要
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation and chronic inflammation, with increasing evidence implicating the gut microbiota in its pathogenesis. Probiotics, such as Lactobacillus rhamnosus GG (LGG), exert anti-inflammatory effects by enhancing gut barrier function and restoring microbial homeostasis, representing a promising therapeutic strategy for SLE. However, conventional probiotic therapies are hindered by poor survival and colonization in the hostile intestinal environment. Here, a polydopamine-coated LGG (LGG@PDA) with improved viability, adhesion, and resistance to oxidative stress is developed. In murine models of lupus, LGG@PDA treatment restored gut and immune homeostasis, enhanced macrophage efferocytosis, reduced autoantibody levels, and ameliorated renal pathology. Metabolomic analysis further identified L-methionine, a metabolite diminished in both lupus mice and SLE patients, as being enriched by LGG@PDA treatment. Functionally, L-methionine enhanced macrophage efferocytosis in a CX3CR1-dependent manner, thereby contributing to the restoration of immune tolerance. Collectively, these findings establish LGG@PDA as a bioengineered probiotic platform that integrates microbiota modulation with immune regulation, highlighting L-methionine as a key metabolic mediator and a promising microbiota-based therapeutic strategy for SLE.
科研通智能强力驱动
Strongly Powered by AbleSci AI